CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TOPCAPI leverages actinomycetes to produce high-value pharmaceutical compounds, including intermediates for antibiotics. By employing systems biology and metabolic engineering, the project aims to enhance the production efficiency of these compounds for medical applications.
TOPCAPI will exploit the natural fabrication power of actinomycetes as microbial cell factories to produce three high value compounds:
GE2270, a starter compound for the semi-synthesis of NAI-Acne, a new topical anti-acne drug in Phase II clinical trials; 6-desmethyl-tetracycline (6DM-TC) and 6-desmethyl 6-deshydro tetracycline (6DM6DH-TC), intermediates for semi-synthetic conversion to medically important type II polyketide tetracyclines (TC), e.g. minocycline, tigecycline, and the novel omadac…
THE UNIVERSITY OF MANCHESTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Armilla Granada
Type: Research institute
Activity type: Research Organisations
SME: No
Slovenia, Ljubljana
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, York North Yorkshire
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
